v3.25.1
Accrued Liabilities (Notes)
 3 Months Ended
Mar. 31, 2025
Accrued Liabilities [Abstract]  
Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities and Other Long-Term Liabilities
    Accrued liabilities consist of the following (in thousands): 
As of
 March 31, 2025December 31, 2024
Salaries and benefits$71,756 $60,815 
Incentive compensation29,124 59,445 
Operating lease liability-ST13,472 15,695 
Accrued sales taxes and other taxes7,201 9,013 
Restructuring accrual8,522 9,945 
Deferred revenue32,485 30,358 
Italy medical device payback provision(1)
25,530 23,937 
Legal accrual3,159 3,425 
Distribution fees14,072 16,548 
Warranties and returns4,070 4,094 
Field service corrective action(2)
29,291 32,844 
Accrued freight9,413 13,206 
Foreign exchange contracts4,335 7,391 
Accrued audit and professional services7,579 7,562 
Defined benefit plan4,276 3,111 
Other14,607 9,534 
 $278,892 $306,923 
___________________________
(1)     Related to potential payments associated with the IMDP (as defined below) as a result of 2015 legislation enacted requiring medical device companies to make payments to the Italian government based on regional expenditure ceilings (see Note 20: Commitments and Contingencies for further details).
(2)     Primarily includes field corrective actions associated with certain products in connection with a 2021 Warning Letter (as defined below) received by Smiths Medical from the FDA following an inspection of Smiths Medical's Oakdale, Minnesota Facility (see Note 20: Commitments and Contingencies for further details).

As of March 31, 2025 and December 31, 2024, certain accrued liability account balances that are part of a disposal group that met the criteria for assets held for sale during the fourth quarter of 2024 were presented as a separate line item "Liabilities held for sale" in our consolidated balance sheet (See Note 4:Assets Held For Sale).
Other long-term liabilities consist of the following (in thousands): 
As of
 March 31, 2025December 31, 2024
Operating lease liability-LT$48,234 $40,777 
Benefits3,896 3,830 
Finance lease liability-LT2,342 2,332 
Deferred revenue9,200 9,045 
Field service corrective action(1)
8,351 6,401 
Other5,614 4,360 
 $77,637 $66,745 
______________________________
(1)    Primarily related to field service corrective actions associated with certain products in connection with a 2021 Warning Letter (as defined below) received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility (see Note 20: Commitments and Contingencies for further details).